LPA Receptor

LPA receptor antagonists and agonists act on receptors for the lipid mediator lysophosphatidic acid (LPA). Six LPA receptors, LPA1 to LPA6, are known, and all belong to the G protein-coupled receptor family. The first, LPA1, was identified in 1996 as the product of ventricular zone gene-1 in the developing cerebral cortex. LPA signaling controls cell migration, proliferation and cytoskeletal change in many tissues. In 2008 LPA1 was linked to fibroblast recruitment and vascular leak in a model of pulmonary fibrosis. Ki16425 and Ki16198 block LPA1 and LPA3, and AM966, AM095 and ONO-7300243 are LPA1 antagonists. GRI 977143 and Radioprotectin-1 act as LPA2 agonists, while AS2717638 antagonizes LPA5.

Items 51-54 of 54

  • Lp(a)-IN-5 hydrochloride
    Cat. No.
    A69555

    Lp(a)-IN-5 hydrochloride

    Lp(a)-IN-5 hydrochloride is a potent lipoprotein (a) (Lp(a)) inhibitor that functions by disrupting the assembly of Apo(a) and ApoB proteins, exhibiting an IC50 value of 0.41 nM. This compound is utilized in research focused on diseases associated with elevated plasma Lp(a) levels, such as various cardiovascular disorders. Its oral bioavailability further enhances its applicability in preclinical studies aimed at understanding the role of Lp(a) in pathophysiology.

    5 mg
    $155.00
    10 mg
    $240.00
    All 5 sizes
  • Muvalaplin
    Cat. No.
    A75845

    Muvalaplin

    Synonyms: LY3473329

    Muvalaplin is an orally active, selective inhibitor of lipoprotein (a) (Lp(a)), targeting the non-covalent interaction between apolipoprotein(a) and apolipoprotein B100. By preventing the formation of disulfide bonds, Muvalaplin effectively reduces Lp(a) levels, as demonstrated in transgenic mouse models and cynomologus monkeys. This compound holds significant potential for research into cardiovascular diseases and dyslipidemia related to elevated Lp(a) levels.

    1 mg
    $120.00
    5 mg
    $305.00
    All 7 sizes
  • LPA5 antagonist 1
    Cat. No.
    A87906

    LPA5 antagonist 1

    LPA5 Antagonist 1 is a highly selective antagonist of the lysophosphatidic acid receptor 5 (LPA5), exhibiting an IC50 of 32 nM. This compound demonstrates significant blood-brain-barrier permeability and anti-nociceptive properties, making it suitable for studies in inflammatory and neuropathic pain. Additionally, LPA5 Antagonist 1 features an alkyne group, enabling its use as a click chemistry reagent for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules.

    5 mg
    $580.00
    10 mg
    $965.00
    All 5 sizes
  • (Rac)-1-Oleoyl lysophosphatidic acid sodium
    Cat. No.
    B10821

    (Rac)-1-Oleoyl lysophosphatidic acid sodium

    Synonyms: (Rac)-1-Oleoyl-sn-glycero-3-phosphate sodium; (Rac)-1-Oleoyl-LPA sodium

    (Rac)-1-Oleoyl lysophosphatidic acid sodium is a racemic isomer of 1-Oleoyl lysophosphatidic acid, targeting lysophosphatidic acid receptors. This compound plays a significant role in modulating various cellular processes including cell proliferation, survival, and migration. It is commonly utilized in research applications focusing on cancer biology, neurobiology, and developmental biology, providing insights into cell signaling pathways and lipid metabolism.

    1 mg
    $50.00
    5 mg
    $165.00
    All 2 sizes

Items 51-54 of 54

Added to your cart

View Cart Checkout

    Loading...